RAPT Therapeutics Announces $150 Million Private Placement RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with significant unmet needs in inflammatory diseases
PowerPoint Presentation ABSTRACT BACKGROUND: FLX475 (tivumecirnon, or TIVU) is a selective CCR4 antagonist designed to block the recruitment of immunosuppressive regulatory T cells (Treg) into the tumor microenvironment The FLX475-02 trial (NCT03674567) is a phase 1 2 study of FLX475 as monotherapy and in combination with pembrolizumab in subjects with advanced cancer Early encouraging data on the biologic effects
PowerPoint Presentation RPT193, a novel CCR4 inhibitor, improves clinical severity of atopic dermatitis and modulates the transcriptomic profile of lesional skin Emma Guttman-Yassky1, Ana B Pavel2, Paola Facheris1, Joel Correa Da Rosa1, Angel Pagan1, Yeriel Estrada1, Robert Bissonnette3, Manu Kumar4, Damian Trujillo4, Josh Rulloda4, Nadine Lee 4, Shoji Ikeda4, Jasmina Jankicevic4,Dave Wustrow4, Dirk Brockstedt4
A combined mregDC and Treg signature associates . . . - RAPT Therapeutics We thank our colleagues at RAPT Therapeutics and scientific advisors for helpful suggestions and discussion This study is in collaboration with Merck Sharp Dohme LLC, a subsidiary of Merck Co , Inc , Rahway, NJ, USA st Spatial profiling was performed (n=2, tumors) with a multicolor IF panel on FFPE tumors
Press Releases | RAPT Therapeutics, Inc. The Investor Relations website contains information about RAPT Therapeutics, Inc 's business for stockholders, potential investors, and financial analysts
Biological activity of FLX475, an oral CCR4 . . . - RAPT Therapeutics FLX475 is a potent and selective CCR4 antagonist, designed to block immunosuppressive regulatory T cell (Treg) migration into the tumor microenvironment (TME), which has the potential to overcome immune resistance and broaden clinical efficacy to a variety of conventional and immunotherapy-based approaches In a recent interim clinical update from the ongoing FLX475-02 Phase 1 2 trial